Leading biomarker and bioanalysis company lays the foundation for future growth and expansion plan
LEIDEN, THE NETHERLANDS, 13 May 2022 – Synexa Life Sciences BV, a global leader in biomarker and bioanalysis research services, announces today that co-founder and CEO Paul O’Riordan will move into the role as the Synexa’s chairman following 19 years in the executive leadership position. CFO & COO Emile Lens, who joined Synexa is 2019, has been appointed as the new CEO with immediate effect.
Subsequently, Nadia Borchards, head of shared services, and Melanie Lucas, global head of operations will adopt the CFO and COO positions respectively.
Paul O’Riordan, Chairman of Synexa Life Sciences, commented:
“I’m looking forward to stepping into the chairman role at Synexa, which will focus on our M&A ventures and building more global strategic partnerships. Emile Lens has been with Synexa for over 2 years and in that time has had a significant impact on our business operations and so I’m excited see his plans in action as chief executive of Synexa to achieve the company’s ambitious growth projections.”
Emile Lens, CEO of Synexa Life Sciences, commented:
“I’m honored to have been asked to take over and lead the executive leadership team of Synexa, while continuing to work closely with Paul in his new role. My focus will be to deliver on our ‘buy and build strategies’. We look to grow Synexa through multiple acquisitions of specialist companies operating within our sector and through the expansion of Synexa’s global footprint by adding capacity and services across our current laboratory sites and opening new sites in new geographies.”
About Synexa Life Sciences
For nearly 20 years Synexa Life Sciences has supported leading biopharma clients across the globe to achieve their clinical milestones through the application of cutting-edge biomarker science. Synexa specialises in the development, validation and delivery of a wide range of complex and custom-designed assays, founded on deep expertise in immunology and the impact of the immune system on human health and candidate drug performance. Since 2019, Synexa has successfully pursued a buy and build strategy, backed by Gilde Healthcare, one of Europe’s largest and most successful health care investors. Over the last two years, Synexa has more than doubled in size and has expanded its capacity in all its global sites substantially.
For Further information please contact:
